Asset
COLESEVELAM HYDROCHLORIDE
Ironwood Pharmaceuticals Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03561090 | phase3 | terminated | 2018-06-20 | 2020-10-07 | Ironwood Pharmaceuticals, Inc. | A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) |
| NCT02637557 | phase2 | completed | 2016-03-01 | 2017-04-26 | Ironwood Pharmaceuticals, Inc. | A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) |
| NCT02030925 | phase2 | completed | 2014-02-01 | 2014-12-01 | Ironwood Pharmaceuticals, Inc. | Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors |
| NCT03856970 | phase1 | completed | 2019-03-11 | 2019-06-25 | Ironwood Pharmaceuticals, Inc. | Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers |
| NCT03561883 | phase3 | completed | 2018-09-06 | 2020-07-28 | Ironwood Pharmaceuticals, Inc. | Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) |
FDA applications (0)
This company has no applications containing this asset.